TABLE 1.

Comparison of clinical data of each group of samples

	High‐throughput sequencing group					qPCR validation group
	SR(n = 3)	PaAF(n = 3)	PeAF(n = 3)	F/X2	P	SR(n = 20)	AF(n = 20)	F/X2	P值
Age(Y)	65.33 ± 7.02	61.33 ± 7.77	59 ± 8.72	0.50	.63	58.30 ± 10.36	55.25 ± 8.52	3	.09
Male	1	1	2	0.9	.64	12	10	0.40	.51
BMI(kg/m2)	27.37 ± 2.22	29.20 ± 2.59	28.67 ± 2.74	0.42	.68	26.91 ± 2.76	28.91 ± 2.65	0.61	.44
Hypertension	0	1	0	2.25	.33	5	6	0.13	.72
Stroke	1	0	0	2.25	.33	4	3	0.17	.68
Blood biochemical parameters
WBC109/L	5 ± 1.46	5.91 ± 0.84	6.87 ± 1.29	1.76	.25	6.02 ± 2	6.85 ± 2.76	1.13	.29
PLT 109/L	186.67 ± 10.07	171.33 ± 16.80	185 ± 17.09	0.94	.44	215.2 ± 46.30	220.30 ± 54.59	0.32	.58
D‐di ug/ml	0.25 ± 0.07	0.22 ± 0.46	0.14 ± 0.31	3.06	.12	0.32 ± 0.26	0.24 ± 0.18	2.20	.15
ALT U/L	23 ± 6.56	13.67 ± 2.52	15 ± 5.57	2.86	.13	27.35 ± 15.04	31.85 ± 23.30	2.40	.13
Scr umol/L	52 ± 13.75	63.67 ± 11.37	76 ± 5.29	3.74	.08	63.90 ± 15.33	71.10 ± 19.78	0.90	.35
UA umol/L	397.76 ± 118.97	339 ± 123.60	407 ± 181.43	0.20	.83	361.10 ± 81.14	350.95 ± 82.61	0.20	.66
TG umol/L	1.94 ± 0.71	2.34 ± 1.71	3.41 ± 1.32	1.01	.42	1.62 ± 0.40	2.28 ± 0.79	9.72	<.01
LDLmmol/L	1.50 ± 0.66	2.51 ± 0.28	2.95 ± 0.58	5.89	.04	2.02 ± 0.60	2.21 ± 0.79	1.61	.21
CRPmmol/L	1.47 ± 0.91	1.23 ± 0.64	1.07 ± 0.06	0.29	.75	1.55 ± 2.81	2.06 ± 1.31	0.74	.46
Cardiac ultrasound
LAAp mm	34.67 ± 2.52	38.33 ± 4.16	45.33 ± 3.51	7.34	.02	31.10 ± 2.85	36.40 ± 5.64	5.34	.03
IVSd mm	7.67 ± 0.58	8.67 ± 0.58	9.00 ± 1.00	2.60	.15	8.2 ± 1.01	8.40 ± 0.88	0.58	.45
LVEF%	62.67 ± 4.04	53.00 ± 2.00	57.00 ± 8.38	1.12	.39	60.20 ± 3.14	55.00 ± 6.37	6.15	.02

Abbreviations: AF, atrial fibrillation; LAAp, anteroposterior diameter of left atrium; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; PaAF, paroxysmal AF group; PeAF, persistent AF group; SR, sinus rhythm; TG, triglyceride.